Status:
UNKNOWN
Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease
Lead Sponsor:
Pharmacology Research Institute
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-85 years
Phase:
PHASE2
Brief Summary
This research study will assess whether AAB-001 is safe, well tolerated and effective for use in patients with Alzheimer's Disease. AAB-001 is a new drug that is not available outside this study. AAB-...
Eligibility Criteria
Inclusion
- Diagnosis of probable AD
- Age from 50 to 85 years, inclusive
- Rosen Modified Hachinski ischemic score less than or equal to 4
- Magnetic Resonance Imaging (MRI) scan consistent with the diagnosis of AD
- Fluency in English
- Stable doses of medications
Exclusion
- Significant neurological disease other than AD
- Major psychiatric disorder
- Significant systemic illness
- History of stroke or seizure
- Weight greater than 120kg (264 lbs.)
- History of autoimmune disease
- Smoking more than 20 cigarettes per day
- Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications
- Prior treatment with experimental immunotherapeutics or vaccines for AD
- Presence of pacemakers or foreign metal objects in the eyes, skin, or body
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
April 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00174525
Start Date
April 1 2005
End Date
April 1 2008
Last Update
May 9 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmacology Research Institute
Los Alamitos, California, United States, 90720
2
Pharmacology Research Institute
Northridge, California, United States, 91324-4625